Oxford lab will know by mid-June if their Covid-19 vaccine works in humans

The vaccine for mumps holds the record for the shortest time to develop an inoculation against disease and that took four years, while the Ebola vaccine’s development path took five years. With about 90 different institutions across the world trying to speed up the process to develop a Covid-19 vaccine; most medical experts think that a realistic time line would be 12 – 18 months. But, the Director of Oxford’s Jenner Institute, Prof Adrian Hill told Biznews at the end of March that he was confident that they could do it much faster and if their vaccine worked; it could be manufactured later this year. A Professor in Medicine at the university, Sir John Bell told the BBC today that “the university was hoping to get some signal about whether it’s working by the middle of June.” Pharmaceutical giant AstraZeneca has agreed to manufacture and distribute Oxford’s Covid-19 vaccine if it proves to be effective. The aim of the partnership is to scale up to produce tens of millions of doses by the end of the year. It now seems that  Prof. Hill confidence’s was justified and a report in Medical Brief says that in the race to provide the world with a vaccine, Oxford University is sprinting the fastest and its effectiveness has been proven in a study in Montana. – Linda van Tilburg

Oxford University way ahead of the pack in race for Covid-19 vaccine

From Medical Brief

In the worldwide race for a vaccine to stop the coronavirus, sprinting fastest is Oxford University, with of their new coronavirus vaccine involving more than 6,000 people by the end of May, reports The New York Times. With emergency regulatory approval, the first few million doses of their vaccine could be available by September, if it proves to be effective.

Most other teams have had to start with small clinical trials of a few hundred participants to demonstrate safety. But scientists at the university’s Jenner Institute had a head start on a vaccine, having proved in previous trials that similar inoculations – including one last year against an earlier coronavirus – were harmless to humans.

The report says that has enabled them to leap ahead and schedule tests of their new coronavirus vaccine involving more than 6,000 people by the end of next month, hoping to show not only that it is safe, but also that it works.

The Oxford scientists now say that with an emergency approval from regulators, the first few million doses of their vaccine could be available by September – at least several months ahead of any of the other announced efforts — if it proves to be effective. Now, they have received promising news suggesting that it might.

Scientists at the National Institutes of Health’s Rocky Mountain Laboratory in Montana last month inoculated six rhesus macaque monkeys with single doses of the Oxford vaccine. The animals were then exposed to heavy quantities of the virus that is causing the pandemic – exposure that had consistently sickened other monkeys in the lab. But more than 28 days later all six were healthy, said Vincent Munster, the researcher who conducted the test.

“The rhesus macaque is pretty much the closest thing we have to humans,” Munster is quoted in the report as saying, noting that scientists were still analysing the result. He said he expected to share it with other scientists next week and then submit it to a peer-reviewed journal.

Immunity in monkeys is no guarantee that a vaccine will provide the same degree of protection for humans. A Chinese company that recently started a clinical trial with 144 participants, SinoVac, has also said that its vaccine was effective in rhesus macaques. But with dozens of efforts now underway to find a vaccine, the monkey results are the latest indication that Oxford’s accelerated venture is emerging as a bellwether. “It is a very, very fast clinical programme,” said Emilio Emini, a director of the vaccine programme at the Bill and Melinda Gates Foundation, which is providing financial support to many competing efforts.

The report says which potential vaccine will emerge from the scramble as the most successful is impossible to know until clinical trial data becomes available. More than one vaccine would be needed in any case, Emini argued. Some may work more effectively than others in groups like children or older people, or at different costs and dosages. Having more than one variety of vaccine in production will also help avoid bottlenecks in manufacturing, he said.

But as the first to reach such a relatively large scale, the report says the Oxford trial, even if it fails, will provide lessons about the nature of the coronavirus and about the immune system’s responses that can inform governments, donors, drug companies and other scientists hunting for a vaccine.

(Visited 2,826 times, 4 visits today)